Search research articles
Contact Us
Filters
Showing results (171-180 of 383) with videos related to
Page
of 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies
Jennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2006
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
Peter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Leukemia Research
|
August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
Francis J Giles, Eric J Feldman, Gail J Roboz, et al.
Cancer
|
March 26, 2004
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251
David A Rizzieri, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy
Megan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study
Alice B Kornblith, James E Herndon, Lewis R Silverman, et al.
Blood
|
August 1, 2002
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
Maria R Baer, Stephen L George, Richard K Dodge, et al.
Blood
|
March 19, 2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus, Giuseppe Saglio, Richard A Larson, et al.
American Journal of Hematology
|
February 5, 2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
Michael B Lilly, Oliver G Ottmann, Neil P Shah, et al.
Haematologica
|
October 1, 2013
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)
Meir Wetzler, Dorothy Watson, Wendy Stock, et al.
Page
of 39
Search research articles
Search
Showing results (171-180 of 383) with videos related to
Sort By:
Page
of 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies
Jennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2006
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
Peter Paschka, Guido Marcucci, Amy S Ruppert, et al.
Leukemia Research
|
August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
Francis J Giles, Eric J Feldman, Gail J Roboz, et al.
Cancer
|
March 26, 2004
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251
David A Rizzieri, Jeffrey L Johnson, Donna Niedzwiecki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 24, 2014
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy
Megan Othus, Frederick R Appelbaum, Stephen H Petersdorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study
Alice B Kornblith, James E Herndon, Lewis R Silverman, et al.
Blood
|
August 1, 2002
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
Maria R Baer, Stephen L George, Richard K Dodge, et al.
Blood
|
March 19, 2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus, Giuseppe Saglio, Richard A Larson, et al.
American Journal of Hematology
|
February 5, 2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
Michael B Lilly, Oliver G Ottmann, Neil P Shah, et al.
Haematologica
|
October 1, 2013
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)
Meir Wetzler, Dorothy Watson, Wendy Stock, et al.
Page
of 39